An experienced executive in the biopharmaceutical industry, Fuad El-Hibri founded Emergent BioSolutions, where he also serves as executive chairman of the board. Fuad El-Hibri remains active in his professional community as a member on the board of the International Biomedical Research Alliance, which operates the NIH Oxford-Cambridge Scholars Program.
The NIH Oxford-Cambridge Scholars Program consists of highly selective PhD and MD/PhD programs. These programs accept some of the brightest scholars from the United States, the United Kingdom, and Europe. Program participants must earn at least a 3.8 GPA during their undergraduate studies and must have demonstrated creativity and excellence in the lab portion of their program.
Thus far, the program’s scholars have published 417 research papers in peer-reviewed journals. Alumni of the four-year program have gone on to complete medical degrees at distinguished schools that include Harvard University and Duke University, while others have accepted faculty and lab positions at University College campuses in London and Oxford, and other distinguished universities across the world. While other graduates have chosen to pursue postdoctoral positions at such institutions as NIH and Cancer Research UK.
To learn more about the International Biomedical Research Alliance and its programs, visit BiomedAlliance.org.
